What is HC Wainwright's Estimate for Belite Bio Q1 Earnings?

Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Stock analysts at HC Wainwright cut their Q1 2025 EPS estimates for Belite Bio in a report released on Tuesday, March 18th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.37) per share for the quarter, down from their previous estimate of ($0.32). HC Wainwright currently has a "Buy" rating and a $100.00 target price on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio's Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.46) EPS.

Other research analysts also recently issued research reports about the stock. Benchmark upped their price objective on shares of Belite Bio from $57.00 to $79.00 and gave the stock a "buy" rating in a report on Tuesday, January 21st. Cantor Fitzgerald restated an "overweight" rating on shares of Belite Bio in a report on Tuesday, March 18th.

Belite Bio Stock Performance

Shares of NASDAQ BLTE traded down $0.45 during midday trading on Thursday, hitting $67.28. 17,485 shares of the stock traded hands, compared to its average volume of 49,850. Belite Bio has a one year low of $31.01 and a one year high of $86.53. The business has a 50 day moving average price of $59.48 and a two-hundred day moving average price of $60.92. The company has a market cap of $2.14 billion, a PE ratio of -60.61 and a beta of -1.54.

Remove Ads

Belite Bio (NASDAQ:BLTE - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02).

Hedge Funds Weigh In On Belite Bio

Large investors have recently bought and sold shares of the stock. Advisors Preferred LLC bought a new stake in shares of Belite Bio during the fourth quarter valued at about $52,000. GAMMA Investing LLC increased its holdings in Belite Bio by 48.1% during the 4th quarter. GAMMA Investing LLC now owns 1,290 shares of the company's stock worth $81,000 after acquiring an additional 419 shares during the period. BNP Paribas Financial Markets bought a new position in Belite Bio in the 4th quarter valued at $155,000. XTX Topco Ltd purchased a new position in shares of Belite Bio during the 3rd quarter valued at $253,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Belite Bio by 7,122.7% in the third quarter. JPMorgan Chase & Co. now owns 6,356 shares of the company's stock worth $298,000 after purchasing an additional 6,268 shares during the period. 0.53% of the stock is currently owned by institutional investors.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.